This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
⚠️ Warnings
• Women of childbearing age should follow effective contraception to avoid pregnancy and must continue contraception for at least one month after taking the last dose of idelalisib.
• Lactating mothers should not breastfeed their babies during idelalisib treatment to protect the babies from harm, and must withhold for at least a month after stopping idelalisib.
• Allergic or hypersensitivity reactions can occur including severe skin reactions during idelalisib treatment and patients must be instructed to consult their physician without delay, if such reactions occur.
• Patients under treatment with idelalisib are more vulnerable to get infections; therefore patients must be advised to report to their physician if any symptoms of infections occur. They must be informed not to ignore even a high-grade fever.
• Similarly, periodic monitoring of blood counts or neutrophils should be performed during idelalisib treatment to assess the presence of neutropenia which is an indicator of an infection.
• Monitor liver function in patients taking idelalisib by frequently testing the levels of liver enzymes (ALT & AST) and bilirubin to recognize and treat liver dysfunction such as jaundice or liver toxicity at an earlier stage.
• Severe diarrhea and colitis may occur in patients under idelalisib treatment, and patients must be taken to the emergency center if the number of bowel movements exceeds six or more, and started on rehydration therapy.
• There is a possibility of pneumonitis in patients taking idelalisib; therefore any new or worsening of airway symptoms such as a cough or difficulty in breathing should be treated accordingly.
• Severe stomach pain occurs during idelalisib treatment due to the erosion or perforation of the intestine which should be informed to the doctor immediately to treat the severity.
